

# Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

NCT05501756

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	Children's Hospital Medical Center, Cincinnati
<b>Enrollment</b>	60 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Patients who are undergoing allogeneic HCT at CCHMC with an alemtuzumab-containing preparative regimen for treatment of a non-malignant disease are eligible.
- For the first 7 patients, patients must have a 10/10 HLA matched related or unrelated stem cell donor, or be receiving a CD34+ selected stem cell product. After the first 7 patients, any donor match may be allowed after data review by the BMT clinicians and the PI.

### Exclusion (10)

- Patients with a history of anaphylaxis to alemtuzumab.
- Patients who have previously received alemtuzumab and have not cleared alemtuzumab prior to the start of the preparative regimen.
- Life expectancy less than 4 weeks.
- Patients receiving dialysis or plasmapheresis at the time of the start of the conditioning regimen.
- Failure to sign informed consent and/or assent, or inability to undergo informed consent process.

... and 5 more (see full listing online)

## Locations (1 total)

---

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States